humans is predominantly latent and persists for the life of the individual (reviewed in reference 41). Recently, it has been shown that EBV is capable of adopting at least three distinct forms of latency (27) . Type III latency is observed upon in vitro infection of B lymphocytes and results in immortalization and continuous proliferation of the infected B cells via the action of a subset of the six EBV nuclear antigens (EBNAs; EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, and EBNA4) and three membrane proteins (LMP1, LMP2a, and LMP2b) expressed in the type III (immortalizing) program. However, in vivo, the type III latency program is likely to be only transiently observed upon initial infection of a naive host, since several of the type III latent antigens elicit a potent cytotoxic T-lymphocyte response resulting in very effective elimination of type III latently infected B cells (reviewed in reference 33).
, and IRF1,2
؊/؊ fibroblasts demonstrated that absence of both IRF1 and IRF2 reduced Qp activity to approximately the same extent as mutation of the IRF-binding site in Qp, strongly implicating IRF2, and perhaps IRF1, in the regulation of Qp activity. Notably, transcription from Qp was not inducible by either alpha or gamma interferon in EBV-negative B cells but rather was shown to be constitutively activated by IRF1 and IRF2. This observation suggests that IRF1 and IRF2 have a previously unrecognized role as constitutive activators of specific genes. Additionally, data presented indicate that a protein complex containing the nonhistone architectural protein HMG-I(Y) binds to the region identified as the major transcription initiation site for Qp. This observation raises the possibility that HMG-I(Y)-induced DNA bending plays a role in the initiation of transcription from Qp.
Epstein-Barr virus (EBV) infection in immunocompetent
humans is predominantly latent and persists for the life of the individual (reviewed in reference 41). Recently, it has been shown that EBV is capable of adopting at least three distinct forms of latency (27) . Type III latency is observed upon in vitro infection of B lymphocytes and results in immortalization and continuous proliferation of the infected B cells via the action of a subset of the six EBV nuclear antigens (EBNAs; EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, and EBNA4) and three membrane proteins (LMP1, LMP2a, and LMP2b) expressed in the type III (immortalizing) program. However, in vivo, the type III latency program is likely to be only transiently observed upon initial infection of a naive host, since several of the type III latent antigens elicit a potent cytotoxic T-lymphocyte response resulting in very effective elimination of type III latently infected B cells (reviewed in reference 33) .
EBV is also capable of entering programs of latency in which the expression of latent antigens is restricted with respect to the type III program. In type I latency, only the EBNA1 protein is expressed (64) . It has recently been shown that EBNA1 peptides do not enter the major histocompatibility complex class I antigen processing and presentation pathway (29, 39, 52) , and cells which express only EBNA1 are not detected by host cellular immune surveillance mechanisms (63) . The type II latency program differs from type I latency only in the expression of variable combinations of LMP1, LMP2a, and LMP2b, in addition to EBNA1. Since the type I latency program was identified, there has been speculation that type I latently infected B lymphocytes represent the lifelong reservoir of virus in immunocompetent, seropositive individuals, and there have recently been several reports which provide evidence that a type I-like form of restricted viral latency does indeed exist in healthy carriers of EBV (6, 51, 60, 85) .
Investigations into the molecular basis of type III and type I latency have demonstrated that distinct promoters are used to drive transcription of the EBNAs in each latent program. In type III latency, transcription of all six nuclear antigens is initiated from either Wp (during initial infection of resting B cells) or Cp (in cycling B cells), and the long primary transcripts are differentially spliced to generate the mature EBNA transcripts (75, 94; see Fig. 1A for a schematic representation of EBV latent transcription and locations of promoters). Recent investigations have shown that transcription of the EBNA1 gene in type I latency is driven by a promoter designated Qp, which is considerably downstream of the type III latency EBNA gene promoters (57, (70) (71) (72) . Qp has an architecture with numerous similarities to eukaryotic housekeeping gene promoters (71, 73) and is silenced during type III latency by the binding of EBNA1 downstream of the transcription initiation site (68, 73; see Fig. 1B for the sequence and structural features of Qp).
Qp-driven EBNA1 gene transcription has been observed in a number of tumor cell lines of different cellular origins (73) , and Qp is likely to initiate the EBNA1 transcripts which are observed in the absence of expression of other EBNA mRNAs in vivo (85) . A number of studies have shown that the type III latency EBNA gene promoters, Cp and Wp, are inactivated by CpG methylation during type I latency (2, 10, 22, 44, 49, 62, 69) , while Qp is at the center of a hypomethylated island and remains active (73) . Although evidence strongly suggests that methylation of Cp and Wp is absolutely required for EBV to stably maintain the type I and II latency programs (73) , almost nothing is known about the specific trans-acting factors which regulate transcription from Qp. We thus initiated an investigation based on our previous characterizations of Qp (71, 73) to identify the trans-acting proteins utilized by EBV to drive EBNA1 gene transcription during restricted viral latency.
in PBS, fixed in ethanol, and stored at 4ЊC for cell cycle analysis by propidium iodide staining, and the second portion was used for luciferase and ␤-galactosidase assays. Luciferase assays and ␤-galactosidase assays (for normalization of luciferase values) were performed essentially as described by Krek et al. (34) , and propidium iodide staining and cell cycle analysis were performed as described by Neuman et al. (56) .
DNase I footprinting and electrophoretic mobility shift analyses (EMSA). The Qp DNase I footprinting construct was generated by cloning bases 1 to 249 (BamHI to PvuII) of the BamHI Q fragment into the BamHI and EcoRV sites of pBluescript-KSϩ (Stratagene). Nuclear extracts were prepared and footprinting was performed as previously described (12) .
For EMSA, crude nuclear extracts were prepared from ca. 10 8 cells by employing a modified version of the protocol described by Dignam et al. (8) . Cells were pelleted by centrifugation, washed once with PBS, and resuspended in 4 volumes of buffer A (10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid [HEPES; pH 7.9], 10 mM KCl, 1.5 mM MgCl 2 , 5 mM dithiothreitol [DTT], 0.5 mM phenylmethylsulfonyl fluoride, 1 g of leupeptin per ml, 1 g of antipain per ml, 0.5 mM NaF, 0.5 mM NaVO 4 ). Cells were incubated on ice for 1 h and lysed by 20 strokes with a Dounce homogenizer. Nuclei were separated from cytosolic components by being spun for 10 s in an Eppendorf Microfuge, and the supernatant was removed by aspiration. Nuclei were resuspended in 3 volumes of buffer B (10 mM HEPES [pH 7.9], 20% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 1 g of leupeptin per ml, 1 g of antipain per ml, 0.5 mM NaF, 0.5 mM NaVO 4 ) and incubated on ice for 30 min. Nuclei were then removed by centrifugation at 4ЊC for 20 min (14,000 ϫ g), and supernatants were aliquoted and stored at Ϫ70ЊC.
Oligonucleotides were synthesized (AnaGen) and then purified on acrylamide denaturing gels (67) and chromatography on SepPak C 18 columns (Waters). Complementary oligonucleotides were mixed at an equimolar ratio in 50 mM NaCl, heated to 90ЊC, and annealed by slow cooling. Labeling (100 ng) was achieved by a Klenow fill-in reaction (67) performed for 1 to 2 h at 4ЊC with [␣-
32 P]dGTP and [␣-32 P]dCTP (New England Nuclear) and unlabeled dATP and dTTP in the labeling reaction. The labeled probe was separated from unincorporated nucleotides by chromatography over Sephadex G25 (Sigma).
For EMSA experiments, nuclear extracts were thawed on ice and 3 l (5 to 10 g) was mixed with 2 l (20 g) of purified bovine serum albumin (New England Biolabs), 0.4 l (2 g) of sheared salmon sperm DNA, 7 l of buffer D (20 mM HEPES [pH 7.9], 0.1 M KCl, 20% glycerol, 0.2 mM EDTA, 1 mM DTT), and 11 l of high-pressure liquid chromatography-grade water (per sample). An unlabeled oligonucleotide competitor (200 ng) was also added to the appropriate samples at this time. This mixture was incubated at room temperature for 20 min, the labeled oligonucleotide was added (1 ng), and the mixture was incubated for a further 20 min at room temperature. For supershift experiments, 2 g of antibody [anti-IRF1 (C-20); mouse-specific anti-IRF1 (M-20), anti-IRF2 (C-19), or anti-ISGF3␥ (C-20) (Santa Cruz Biotechnology); or polyclonal anti-human HMG-I(Y) (82) (a gift from Dimitris Thanos)] was then added, and samples were incubated at room temperature for an additional hour. Samples were loaded onto a 4% native acrylamide gel (40:1 acrylamide-bisacrylamide) and electrophoresed at 4ЊC at no higher than 45 mA (0.5ϫ TBE buffer [1ϫ TBE buffer is 90 mM Tris, 64.6 mM boric acid, and 2.5 mM EDTA, pH 8.3]). Gels were run for 2 to 5 h, transferred to Whatman paper, and dried. Retarded complexes were visualized by autoradiography (1 to 16 h at room temperature). For the oligonucleotides employed in EMSA related to the IRF studies, see Fig.  4A . The EBNA1 site oligonucleotides used (see Fig. 12A and B) are as follows (only the sense strand is shown): 2ϫEBNA1, 5Ј-CGCGCGGGATAGCGTGC GCTACCGGATGGCGGGTAATACATGCTATCCTTACCTAG-3Ј; upEBNA1, 5Ј-CTAGAAAAGGCGCGGGATAGCGTGCGCTGGATC-3Ј; dwnEBNA1, 5Ј-CTAGACATGCTATCCTTACATTTTGGATC-3Ј.
RESULTS
A region immediately upstream of Qp binds cellular factors and is required for reporter gene activity. To identify candidate cis-acting elements which might play a role in the regulation of Qp activity, crude nuclear extracts prepared from the group I BL-cell lines Akata and Rael (type I latency), the group III BL-cell line Jijoye (type III latency), and the EBVnegative BL-cell line DG75 were used in a DNase I protection analysis. All extracts protected a region extending approximately from Ϫ22 to Ϫ1 relative to the Qp transcription initiation site ( Fig. 1B and 2 ). Since an identical protection pattern was observed with extracts prepared from both EBV-positive and EBV-negative cell lines, the factors binding to this region must be of cellular origin and not virally encoded. In addition, a distal region of Qp appeared to be protected from DNase I digestion by crude nuclear extract prepared from Rael cells (Fig. 2) . This region corresponds to approximately Ϫ97 to Ϫ127 relative to the Qp transcription initiation site. The significance of this protection is uncertain, since it was not observed with extracts prepared from the other cell lines.
To define the minimal sequences upstream of the Qp initiation site required for reporter construct activity, the previously described Ϫ1730FQUCAT construct (73; see the legend to Fig. 3 ) was subjected to deletion analysis. We have previously demonstrated by S1 nuclease protection that an equivalent reporter construct (FQUglobin, in which the CAT gene was replaced with the rabbit ␤-globin gene) specifically initiated transcription from Qp (71) . Additionally, studies have shown that sequences downstream of the EBNA1-binding sites (i.e., beyond ϩ75 relative to the Qp transcription initiation site) are not required for Qp activity (73, 73a) . A series of reporter constructs containing truncations of upstream sequences was derived, and their activities were assessed by transient transfection into group I BL-cell lines (Fig. 3) . This analysis demonstrated that reporter gene activity was significantly diminished when sequences between Ϫ35 and Ϫ4 bp relative to Qp were deleted but was relatively unaffected by deletion of sequences upstream of Ϫ35 bp. Thus, this deletion analysis demonstrated that a 31-bp region, which includes most of the cellular factor binding site identified by DNase I footprinting, contains a cis element(s) involved in upregulation of transcription initiation from Qp.
Identification of an ICS in Qp.
Promoters which lack a TATAA element (such as Qp) are thought to direct RNA polymerase II to the site of transcription initiation primarily via an element called an initiator (Inr) at the transcription start site (reviewed in reference 90). Since the cellular factor binding site directly upstream of the Qp start site is important for Qp reporter activity, this factor may represent the Qp Inr element (QpInr). To further define the factors that bind to the putative QpInr element, a DNA fragment corresponding to the region protected from DNase I digestion was synthesized (Fig.  4A ) and analyzed in an EMSA. Two major complexes were identified by using crude nuclear extract prepared from the group I BL-cell line Rael (Fig. 4B) , as well as with nuclear extracts prepared from other group I BL-cell lines, LCLs, and EBV-negative BL-cell lines (data not shown). The faster-migrating (lower) complex (indicated by an arrow in Fig. 4B ; note that this complex is actually composed of two distinct bands) and the slower-migrating (upper) complex were both competed for by an excess of the unlabeled QpInr oligonucleotide, demonstrating that binding is specific (Fig. 4B) .
Inspection of the QpInr region revealed a strong homology to the consensus binding site for members of the IFN response factor (IRF) family (Fig. 4A) . Indeed, the lower complex was competed for by a double-stranded oligonucleotide (ISRE) containing the ICS from a typical IFN-inducible gene, ISG15 The bent arrow denotes the major transcription initiation site identified by S1 nuclease protection (71) . A region protected by crude nuclear extracts from DNase I digestion (see Fig. 2 ) is indicated by the bracket. Horizontal arrows within the DNase I footprint indicate a repeated sequence motif, and the homology to a characterized IFN-stimulated response element (ISRE) from the ISG15 promoter (40) is also shown. The low-affinity EBNA1-binding sites, the Q exon splice site, and an inverted CCAAT box are also indicated. (40) (Fig. 4B) . However, binding of the slower-migrating complex was not competed for by the ISRE oligonucleotide. Furthermore, competitor oligonucleotides containing a minimal mutation in the core of the ICS (m-AT) which eliminates a universally conserved G and abrogates binding of IRF family members (79) were unable to compete for the lower complex (Fig. 4B , QpInr m-AT and ISRE m-AT). Finally, a smaller oligonucleotide (QpInr-IRF) which contains only the QpInr putative IRF site was able to compete for the lower complex but was unable to compete for the upper complex. The latter result, in conjunction with the failure of the ISRE oligonucleotide to compete for the upper complex, indicates that the slower-migrating (upper) complex requires sequences other than (or in addition to) those required for IRF binding.
To further investigate cellular factor binding to the QpInr putative ICS, EMSA were carried out by employing crude nuclear extracts from a panel of cell lines (Fig. 5 ) and either the QpInr-IRF probe or the ISG15 ISRE probe (Fig. 4A contains the probe sequences). The patterns of complex formation obtained with the QpInr-IRF probe were very similar with all of the nuclear extracts employed (Fig. 5) , suggesting that the cellular factors involved are ubiquitous. However, with the ISRE probe, the EMSA pattern obtained with extracts prepared from B cells was distinctly different from that observed with extracts prepared from either the T-cell line Jurkat or the epithelial cell line HeLa or CNE2. Based on the studies of Bovolenta et al. (5), the additional complex observed with the B-cell extracts and the ISRE probe is likely to reflect binding of the IRF family member ICSBP, which is expressed only in lymphoid tissues (but is also known not to be expressed in Jurkat cells) (5, 55) . ICSBP heterodimerizes with IRF1 and IRF2, and such heterodimers are reported to bind to ICS sites and inhibit promoter activity in unstimulated cells (5, 92) . Notably, this complex does not appear to form with the QpInr ICS; rather, the complex formed appears to be identical to the complex observed with extract from nonlymphoid cell lines and FIG. 2. DNase I footprinting analysis of the region upstream of Qp. Footprinting was carried out by employing crude nuclear extracts prepared from the indicated cell lines as described in Materials and Methods. The sequence of the core region protected from digestion is indicated to the left, and the ICS is underlined.
FIG. 3.
Activities of Qp reporter constructs demonstrating that sequences upstream of Ϫ35 bp are not required for efficient transcript initiation. The indicated reporter constructs were transfected in the group I BL-cell lines Akata, Mutu I, and Rael as described in Materials and Methods. CAT activities are given relative to the activity of a CAT reporter construct driven by a minimal promoter composed of the ␤-globin gene TATA box. An upstream promoter, Fp, which is active during the early stages of lytic replication (70) is also shown. the ISRE probe (Fig. 5) , suggesting that the complex bound to the QpInr-IRF oligonucleotide does not contain ICSBP.
IRF1 and IRF2, but not ISGF3␥, are bound to the Qp ICS. To determine whether known members of the IRF family might be involved in binding to the Qp ICS, specific antibody reagents were employed in EMSA. When cell extracts prepared from the Rael group I BL-cell line were used in conjunction with the QpInr-IRF oligonucleotide probe, an antibody which specifically recognizes IRF2 (Santa Cruz Biotech) was able to supershift the faster-migrating complex almost completely (note that with the QpInr-IRF oligonucleotide probe, the slower-migrating complex observed with the QpInr oligonucleotide did not form) (Fig. 6 ). An antibody which specifically recognizes IRF1 (Santa Cruz Biotech) was able to generate a weak supershift, suggesting that a small fraction of this complex reflects IRF1 binding (data not shown). However, when an antibody which recognizes the IRF family member ISGF3␥ (p48 subunit of the ISGF3 transcription factor [28, 89] ; Santa Cruz Biotech) was employed, no supershift was detected ( Fig. 6 ), indicating that this factor is most likely not involved in binding to this site. A very faint complex observed below the major ISRE-bound complex (but not below the complex bound by the QpInr-IRF oligonucleotide; compare the JC5 lanes in Fig. 5 ) was reproducibly supershifted by the anti-ISGF3␥ antibody, demonstrating that this antibody is functional and specific (data not shown). Others have also observed that unstimulated cells contain the ISGF3␥ protein, which binds to the ISG15 ISRE oligonucleotide (28) and migrates faster than IRF1 and IRF2 homodimers (5).
To further examine IRF1 and IRF2 binding to the Qp ICS, extracts were prepared from fibroblast cell lines established from mice lacking either IRF1 (IRF1
), or both IRF1 and IRF2 (IRF1,2 Ϫ/Ϫ ) (45) . Initially, the EMSA pattern obtained with a cell extract prepared from wild-type NIH 3T3 cells was assessed by employing the QpInr probe (Fig. 7) . The pattern observed was indistinguishable from the pattern observed with extracts prepared from human cell lines (compare Fig. 7 with Fig. 4B ). As previously observed with group 1 BL extracts (see above), the QpInr-IRF oligonucleotide and the ISRE oligonucleotide competitors competed for the faster-migrating (lower) complex but not the upper complex. As expected, the ISRE m-AT oligonucleotide competitor did not compete for either complex. An extract prepared from the double-knockout cell line (IRF1,2 Ϫ/Ϫ ) was able to form only the upper complex (Fig. 7) , substantiating the antibody supershift evidence that the faster-migrating complex is composed of IRF2 and IRF1 binding. These observations also indicate that the formation of the upper complex does not involve either IRF1 or IRF2, consistent with the failure of antibodies which recognize these factors to supershift this complex (data not shown).
When an extract prepared from the IRF1 Ϫ/Ϫ cell line was used in conjunction with the QpInr-IRF probe, the observed banding pattern of the faster-migrating complex was indistinguishable from that observed with an extract from unmutated cells (Fig. 8A) . A similar pattern was also observed when the labeled ISRE probe was employed, although an additional, slower-migrating band was also observed (Fig. 8A) . As shown above, the faster-migrating complex was competed for by self and the ISRE competitor oligonucleotide probe but not by the ISRE m-AT mutant probe (Fig. 8A) . Finally, antibodies against IRF2 supershifted the QpInr-IRF-bound complex nearly completely, while antibodies which specifically recognize IRF1 or ISGF3␥ were unable to supershift this complex. When an extract prepared from the IRF2 Ϫ/Ϫ cell line was employed in conjunction with the QpInr-IRF probe, a weak complex was observed which migrated with the leading edge of the faster-migrating complex (which, as indicated above, appears to be composed of two distinct bands). This complex was competed for by self and the ISRE but not by the ISRE m-AT mutant, and it was supershifted only by the anti-IRF1 antibody ( Fig. 8A and B) . This result suggests that IRF1 binding is a small proportion of the faster-migrating complex in wild-type cells, although it is also possible that IRF1 binding might occur only in the absence of IRF2. The striking similarity of the IRF2-containing complexes formed with an extract prepared from IRF1
Ϫ/Ϫ cells to those formed with an extract from IRF1-containing cells appears to support the latter contention and also raises the possibility that heterodimers composed of IRF2 and another IRF family member are involved in the regulation of Qp. These results also demonstrate the specificity of the antibody reagents employed in the EMSA and provide strong support for the identification of IRF2 as the major cellular factor in unstimulated cell binding to the Qp ICS.
Mutation of the Qp ICS has a variable effect on Qp activity. To assess the impact of mutation of the Qp IRF-binding site on promoter activity, Qp reporter constructs were generated in which the m-AT mutation (which was shown above to inhibit IRF binding; for specific mutations, refer to Fig. 4A ) was introduced into the Qp IRF-binding site. Both the unmutated and m-AT mutant Qp reporter constructs were transiently transfected into a panel of EBV-positive and EBV-negative cell lines (Fig. 9A) . In all cases, the m-AT mutation significantly diminished activity, although the magnitude of this effect varied between cell lines. In the EBV-negative HeLa and DG75 cell lines, Qp activity was diminished 15-to 20-fold. The effect of the m-AT mutation in the group I BL-cell lines Mutu I and Rael was more modest, giving rise to only a five-to sixfold reduction in activity. It should be noted that in the latter cases the m-AT mutant exhibited significant activity, indicating that IRF binding is not essential for Qp activity in some cell lines.
To determine whether the identification of IRF binding by EMSA correlated with Qp activity in vivo, the wild-type and m-AT mutant Qp reporter constructs were introduced into mouse fibroblast cell lines lacking either IRF1, IRF2, or both IRF1 and IRF2 (45) (Fig. 9B ). When these reporter constructs were transfected into the wild-type (NIH 3T3) cell line, the effect of the m-AT mutation was of a magnitude similar to that observed in the group I BL-cell lines. The IRF1 Ϫ/Ϫ cell line gave results very similar to those obtained with the wild-type NIH 3T3 cell line, while the impact of the m-AT mutation was slightly diminished in IRF2
Ϫ/Ϫ cells. Importantly, when both IRF1 and IRF2 were knocked out, the activities of the wild- (Fig. 8B ) and can upregulate Qp activity (in the absence of IRF2; Fig. 9B ). This observation suggests that either (i) Qp is maximally active in uninduced cells and thus is not responsive to increased levels of IRF1 protein, (ii) IRF2 has a substantially higher affinity than IRF1 for the Qp ICS and increased levels of IRF1 therefore do not significantly influence transcription from Qp, or (iii) most of the additional IRF1 produced following IFN treatment is sequestered in complexes which do not bind with high affinity to the Qp ICS (such as IRF1-ICSBP heterodimers; Fig.  5 ). Further experiments are required to distinguish between these possibilities.
Since Qp does not appear to be IFN inducible and the Qp ICS does not bind ISGF3␥ in vitro (see above), the Qp ICS element was compared with the sequence of a well-characterized ICS element from the IFN-inducible gene ISG15 ( Fig. 10 ; designated ISRE and QpInrIRF, respectively) to identify nucleotide differences which might be responsible for these atypical properties of the Qp ICS. This comparison revealed that there are five nucleotide differences between ISRE and QpInrIRF, at positions 1, 3, 8, 14, and 17. In a previous study, the in vitro binding properties of the ICS element from the IFNinducible gene ISG15 (ISRE) and the ICS element from the IFN-␤ gene (PRDI) were compared, revealing that whereas ISRE can bind either IRF1 or ISGF3␥ with high affinity, PRDI binds only IRF1. For each of the six positions (of the 15 core nucleotides) at which the two ICSs differed, a mutant ISRE oligonucleotide was generated in which the corresponding PRDI nucleotide was substituted at that position and the binding properties of these mutant oligonucleotides were analyzed. One of these substitutions, corresponding to the boxed nucleotide (position 14) in Fig. 10 , was found both to reduce the affinity of ISRE for ISGF3␥ and to increase its affinity for IRF1 (89) . Interestingly, QpInrIRF shares this same C-to-G substitution with the PRDI element, and this is the only position where both the ISRE and PRDI sequences differ and the Qp position matches that of the PRDI element.
Since the ICS elements of Qp and the IFN-␤ promoters share certain properties (neither bind ISGF3␥ in vitro or confer IFN inducibility upon its promoter [see above and references 26 and 89]), the sequences of other ICS elements were examined. This sequence analysis (Fig. 10) 59) , which is consistent with the previously described consensus binding site for ISGF3␥, GGRAAAR(A/T)GAAACAR (40) . In contrast, the promoters having an ICS element with a G at position 14 ( Fig. 10 ) have generally been characterized as non-IFN-␣/␤ inducible, with the ICS playing the role of a constitutive activator of transcription. Qp (see above), the IFN-␤ promoter (26) , and all characterized IFN-␣ promoters (14) are not inducible by IFNs and have a G at position 14 of the ICS element which mediates constitutive activation of the promoter. It should also be noted that although the IFN-␣ and IFN-␤ promoters are both induced by virus, this induction has been shown to be mediated by factors other than IRF1 and IRF2 (14, 83) . Additional examples of constitutive ICS elements are provided by the TAP1 and VCAM1 promoters. Although the VCAM1 (74) and TAP1 (48) promoters are inducible by IFN-␥, this induction is not mediated through the ICS elements and detailed analyses of these promoters have shown that one function of the ICSs of these two promoters is constitutive positive modulation of transcription. Finally, the histone H4 promoters of the FO108 gene (88) and of the other known human, mouse, and rat histone H4 genes (86) contain ICS elements with a G at position 14. The FO108 ICS element has been studied in considerable detail, and IRF1 and IRF2 have been shown to activate transcription of this histone H4 gene (88) and may also cooperate with proteins which confer cell cycle regulation on this promoter (87; see below). To our knowledge, the histone H4 promoters have not been shown to be IFN inducible. Thus, there appear to be a number of promoters which contain ICS elements that have a G (versus a C) at position 14 and are not responsive to IFN-␣/␤ stimulation, presumably due to a reduced affinity for ISGF3␥ (see above and reference 89). Such promoters are positively regulated by binding of IRF1 (and, in some cases, IRF2 [88] ) to these variant ICS elements (Fig. 10) .
Transcription from Qp is constitutive. To date, the only other promoter for which positive regulation by both IRF1 and IRF2 has been demonstrated is the histone H4 promoter FO108 (88) . Transcription from the FO108 promoter is cell cycle regulated, with peak transcription occurring during S phase. The FO108 ICS is found in the cell cycle element of this promoter, and the ICS overlaps with a binding site for a distinct complex containing CDC2, cyclin A, and a member of the RB family (87) . Similar to the histone H4 genes, the only known requirement for EBNA1 in EBV-infected cells involves the binding of EBNA1 to the EBV latent origin of replication (oriP) during S phase of the cell cycle, thereby allowing the EBV episome to be replicated coordinately with cellular genomic DNA (98, 99) . Thus, EBNA1 might be produced in a cell cycle-regulated manner, with peak production occurring [40] , histone H4 [88] , PRDI [89] , IFN-␣1 [14] , VCAM1 [74] , TAP1 [48] , H2K b IRS [30] , factor B [96] , 2Ј-5Ј OAS [66] , and 6-16 [59] ). The nucleotide at position 14, which appears to correlate with IFN-␣/␤ inducibility, is boxed. during S phase, analogous to the regulation of the histone H4 gene. Additionally, a previous study (76) reported an undefined E2F complex binding to a region of Qp overlapping the EBNA1-binding sites. E2F is a heterodimeric complex consisting of an E2F protein and a DP protein, which acts on a number of promoters to enable cell cycle-regulated transcription with peak activity occurring in late G 1 -early S phase (reviewed in reference 35). Those investigators postulated that E2F binding might result in cell cycle regulation of Qp, although no data testing this hypothesis was presented.
To determine whether Qp activity is cell cycle regulated or constitutive, the Ϫ1730FQULuc and Ϫ1730FQULuc/m-AT constructs (identical to the Ϫ1730FQUCAT and Ϫ1730FQUCAT/ m-AT constructs, respectively, except that the CAT gene has been replaced with the luciferase gene; the luciferase protein has a much shorter half-life than the CAT protein and is thus preferred for cell cycle analyses) were transfected into NIH 3T3 cells. These cells were cotransfected with pCMV-␤Gal so that the activities observed at various time points could be normalized to an internal standard. The transfected cells were then serum starved to synchronize the cells at G 0 and then released from growth arrest via addition of serum. The NIH 3T3 transfectants were harvested at eight time points ranging from 0 to 24 h postrelease. Cells were split into two fractions; the first fraction was used in a luciferase assay and a ␤-galactosidase assay to determine normalized Qp activity, and the second aliquot was stained with propidium iodide to determine the cell cycle distribution. As shown in Fig. 11 , Ϫ1730FQULuc activity remained essentially unchanged over the time course, even though the number of cells in S phase ranged from approximately 18% at t ϭ 6 h to 60% at t ϭ 12 h. Analogous results were obtained with the Ϫ1730FQULuc/m-AT construct (data not shown). The above evidence thus indicates that Qp activity is not cell cycle regulated.
Additionally, we have been unable to confirm the results of Sung et al. (76) . Although the region of the Qp EBNA1 sites identified as an E2F-binding site by Sung et al. (76) is capable of binding in vitro-translated GST-E2F-1, it is not clear that the cellular factor from Jurkat cell extracts which they observed in EMSA contained E2F. Indeed, we have detected a relatively weak protein complex which has the properties reported by Sung et al. (76); specifically, the complex binds in the region which represents approximately the middle third of the Qp EBNA1-binding site region, and this complex is competed for by an oligonucleotide encoding the E2F-binding site from the c-myc promoter but is not competed for by oligonucleotides encoding the E2F sites from the E2F-1 promoter or the dihydrofolate reductase promoter (76; data not shown). However, in contrast to the weak supershift of this Qp-bound protein complex with an anti-E2F-1 antibody reported by Sung et al. (76), we observed no supershift with an anti DP-1 antibody (or with an antibody directed against E2F-1), although the E2F complexes bound to an oligonucleotide encoding the dihydrofolate reductase promoter E2F-binding site were completely supershifted by this same anti-DP-1 antibody (data not shown). Based on the above data, it seems highly unlikely that an E2F complex binds in the Qp EBNA1 site region. All evidence thus supports the conclusion that transcription from Qp is consti- FIG. 11 . Evidence that Qp is not cell cycle regulated. The Ϫ1730FQULuc and pCMV-␤Gal reporter plasmids were transfected into NIH 3T3 cells, and the cell cycle was arrested by serum starvation for 48 h as described in Materials and Methods. Following addition of 20% serum, aliquots of transfected cells were harvested at the indicated time points and analyzed for DNA content by propidium iodine staining, as well as ␤-galactosidase and luciferase activities. ␤-Galactosidase activity was used to normalize for variability in transfection efficiency and sample handling. Symbols: s, relative Qp activity; F, cells in S phase. tutive, consistent with its housekeeping promoter architecture (71, 73) .
The cellular architectural protein HMG-I(Y) binds to the QpInr. The above analyses provide substantial evidence that transcription from Qp is upregulated by the binding of IRF2 and IRF1 to an ICS immediately upstream of the site of transcription initiation (Fig. 1B shows its location) . However, EMSA identified two complexes binding to the QpInr oligonucleotide (Fig. 4A shows the sequence) , and oligonucleotide competition and gel supershift analyses indicated that IRF1 and IRF2 are components of only the faster-migrating lower complexes but not the slower-migrating upper complex. The EMSA also demonstrated that a shorter oligonucleotide, QpInr-IRF (Fig. 4A) , bound only the IRF2-IRF1 complex and not the upper complex (Fig. 4B and 5) . Thus, the additional bases 3Ј of the ICS (5Ј-TTGAAAAGGC-3Ј) appear to be necessary for binding of the upper complex to the QpInr oligonucleotide. Since Qp has certain functional characteristics in common with the IFN-␤ promoter, namely, positive regulation by a non-IFN-inducible ICS, the binding sequence preferences of transcription factors known to bind to the minimal IFN-␤ promoter were examined to identify candidates which might bind to 5Ј-TTGAAAAGGC-3Ј. This analysis identified the high-mobility group protein HMG-I(Y), which binds to the sequence 5Ј-GGGAAATTCC-3Ј in the IFN-␤ promoter (82) . Although this sequence is not strikingly similar to the Qp sequence shown above, HMG-I(Y) is known to have a rather loose specificity for A-T-rich sequences (61) , which the motifs in Qp and the IFN-␤ promoter do have in common. EMSA were thus performed with the QpInr oligonucleotide, Rael crude nuclear extracts, and various amounts of a polyclonal anti-human HMG-I(Y) antibody (kindly supplied by D. Thanos). The anti-HMG-I(Y) antibody partially supershifted the upper (non-IRF1/2) complex, and the amount of material supershifted increased with the amount of antibody added (Fig.  12A ). Additionally, we had previously observed that a complex which binds to the 5Ј end of the Qp upstream EBNA1-binding site (upEBNA1 oligonucleotide) comigrated with the QpInr upper complex. This comigrating upEBNA1-bound complex was also supershifted in a dose-dependent manner by the anti-HMG-I(Y) antibody (Fig. 12A) .
Since the experiments in Fig. 12A suggested that the comigrating complexes bound to the QpInr and upEBNA1 oligonucleotides both contain HMG-I(Y), competition analyses were performed to provide evidence that these two complexes have identical (or overlapping sets of) constituents. Crude Rael cell nuclear extracts were used in an EMSA with the labeled QpInr probe, and competitions were performed with either the intact Qp EBNA1 sites (2ϫEBNA1 oligonucleotide), the 5Ј third of the Qp EBNA1 site region (upEBNA1 oligonucleotide), or the 3Ј third of the Qp EBNA1 site region (dwnEBNA1 oligonucleotide). This competition demonstrated that both the 2ϫEBNA1 and the upEBNA1 oligonucleotides competed specifically for the HMG-I(Y)-containing complex bound to the QpInr (but not the IRF1-IRF2 complex), whereas the dwnEBNA1 oligonucleotide did not compete for this complex (Fig. 12B) . It is important to note that although the sequence of the upEBNA1 oligonucleotide overlaps partially the QpInr oligonucleotide (bases GAAAAGGC), the 2ϫEBNA1 oligonucleotide does not include any overlapping sequence. The protein complex(es) containing HMG-I(Y) appears to bind to two distinct regions: the Qp sequences included in the 3Ј end of the QpInr oligonucleotide and the sequences at the 5Ј end of the 2ϫEBNA1 oligonucleotide. 
DISCUSSION
In this study, regulation of the type I latency EBNA1 promoter, Qp, was examined. Transient transfection of group I BL-cell lines employing a series of reporter constructs having nested 5Ј deletions demonstrated that sequences upstream of Ϫ35 bp have little impact on reporter gene activity, while sequences between Ϫ35 and Ϫ4 bp significantly upregulated Qp activity. A sequence which overlaps the region defined as important for enhancement of Qp activity was protected from DNase I cleavage (Ϫ22 to Ϫ1 bp) in an in vitro footprinting assay employing nuclear extracts from EBV-positive and -negative BL-cell lines. EMSA using crude nuclear extracts also demonstrated specific in vitro binding of two predominant protein complexes to an oligonucleotide spanning the region protected from DNase I digestion. Further analyses were performed with specific antibody reagents, oligonucleotide competitors, and nuclear extracts from human cell lines and fibroblast lines derived from IRF1
Ϫ/Ϫ , and IRF1,2
mice. These studies demonstrated that the faster-migrating EMSA complex represents primarily binding of IRF2, with IRF1 representing a small portion of the complex. Several lines of evidence indicate that the binding of IRF2 and IRF1 observed in vitro is responsible for the upregulation of Qp by the Ϫ35 to Ϫ4 region identified by deletion analysis. First, the same mutation (m-AT) which abolishes the binding of IRF1 and IRF2 in vitro results in a reduction in Qp activity to approximately the same extent as that caused by deletion of the sequences between Ϫ35 and Ϫ4 bp. Also, analysis of reporter construct activity in IRF1 and IRF2 mutant cell lines demonstrated that cell lines having either IRF1 or IRF2 (or both factors) generated higher levels of transcription from the wild-type Qp construct than from the construct having the m-AT ICS mutation. However, in cells lacking expression of either IRF1 or IRF2, no difference in reporter gene activity was observed between wild-type and m-AT mutant Qp constructs.
Analysis of the ICS region from Qp, as well as from a number of other promoters, strongly suggests the existence of two distinct classes of ICS elements which can be functionally distinguished by the presence of either a C or a G at position 14 (Fig. 10) . The C-14 variants are responsive to induction by IFN-␣/␤ due to their high affinity for ISGF3␥ (28, 40, 58) , which is the primary DNA-binding component of ISGF3, a multisubunit transcription factor which mediates the response to IFN-␣/␤ (see below). In contrast, this report and previously published data (89) suggest that the G-14 variants have a reduced affinity for ISGF3␥ but bind IRF1 and IRF2 with high affinity. The latter ICS elements are not IFN responsive and are capable of constitutively activating transcription (14, 26, 48, 74) .
EMSA also strongly suggest that the predominant lymphocyte-derived complex bound to the ISG15 ISRE probe is an IRF2-ICSBP (and/or an IRF1-ICSBP) heterodimer, whereas the Qp ICS appears to have a much lower affinity for the ICSBP heterodimeric complexes. Since ICSBP-containing heterodimers inhibit transcription (5, 54) , it seems likely that promoters of IFN-stimulated genes, such as ISG15, are repressed in unstimulated B cells (55) by the binding of the ICSBP-IRF2 and ICSBP-IRF1 heterodimers. Indeed, ICSBP is capable of repressing multiple IFN-responsive promoters (54, 92) and this repression is overcome by treatment of cells with IFNs (92) . In contrast, ICS elements which provide constitutive activation, such as the Qp ICS, are likely to bind IRF2 and IRF1 homodimers preferentially rather than the inhibitory ICSBP-containing heterodimers. It is compelling to speculate that all C-14 ICS elements (IFN stimulated) bind ICSBP-IRF1 and ICSBP-IRF2 heterodimers with higher affinity than IRF1 and IRF2 homodimers, whereas the opposite is true of the G-14 ICS elements (constitutive activators). However, this hypothesis has not been rigorously tested.
IRF1 was originally cloned from a cDNA expression library based on its affinity for a synthetic oligonucleotide (AAGTGA) 4 . A single hexamer of this sequence and several similar purine-rich hexamers were found in the virus-inducible region of the IFN-␤ promoter, and IRF1 was believed to be responsible for both virus-induced transcription of the IFN-␤ gene and upregulation of transcription of genes induced by IFN-␣/␤ (50). However, subsequent research has revealed that IRF1 is a member of a large family of transcription factors which bind to similar to identical sequences. Evidence indicates that most IFN-induced genes are activated primarily by the multisubunit gene ISGF3 (28, 40, 58) and that NF-B is the principal mediator of virus induction of the IFN-␤ gene (58, 83) . Indeed, targeted disruption of the IRF1 gene did not result in diminished production of IFN-␣/␤ in response to virus infection, and the induction of several IFN-induced genes was also normal (65) . The IRF1 Ϫ/Ϫ mouse did show certain unexpected defects, including substantially decreased production of CD8 ϩ thymocytes (45) . Additionally, transcription of inducible nitric oxide synthase by macrophages in response to stimulation with IFN-␥ and lipopolysaccharide is critically dependent upon IRF1 (25) , as is production of interleukin-1␤ converting enzyme by thymocytes in response to concanavalin A and ␥ irradiation (78) . Multiple lines of evidence thus indicate that the principal functions of IRF1 are not related to virus-stimulated or IFN-mediated responses.
As in the case of IRF1, the principal role of IRF2 seems to have little to do with its initially ascribed function. IRF2 was cloned on the basis of sequence homology with the IRF1 gene, and functional studies suggested that IRF2 can act as a repressor of IRF1-mediated activation of the IFN-␤ gene, as well as other promoters which could be induced by IRF1 (19) . Although IRF2 knockout mice indeed demonstrated moderately (two-to threefold) increased peak levels of IFN␣/␤ in response to viral infection, the kinetics of induction were identical (45) . In fact, postinduction repression of the IFN-␤ gene has been shown to be mediated by a non-IRF family protein, PRDI-BF1, which binds to the IFN-␤ PRDI element (26) , and perhaps also by the binding of homodimers of the rel family protein p50 to the PRDII element (83) . Constitutive repression of the IFN-␤ gene is believed to be mediated by the binding of an unidentified factor to a region which overlaps the PRDII domain (but not the PRDI-ICS site) (15, 16) . IRF2 is thus not responsible for the repression of transcription from the IFN genes, and it does not contribute to the postinduction decrease in IFN gene transcription. However, the IRF2 Ϫ/Ϫ mice did demonstrate a generalized hematopoietic defect in which the most readily observed phenotype was a reduction in the number of mature B and T lymphocytes in the bone marrow (45) . The observations that overexpression of IRF2 leads to oncogenic transformation (20) and that IRF1 is a tumor suppressor (80) which can overcome IRF2-mediated transformation (20) underscores the above evidence that IRF1 and IRF2 play major roles in the regulation of diverse processes relating to cell growth. Analysis of the available evidence thus argues that a major role (or perhaps even the primary role) of IRF1 and IRF2 is the constitutive activation of a number of different promoters and that the absence of this transactivation in IRF1 and IRF2 knockout mice may account for the observed defects in processes related to growth and development (reviewed in reference 81).
Recently, it was reported that both IRF1 and IRF2 contribute to the positive regulation of the histone H4 gene FO108 (88) . A latent activation domain of IRF2 had previously been characterized by investigators who speculated that IRF2 could act as a positive transcriptional regulator under certain circumstances (97) . Qp provides a second example of a promoter that is positively regulated by both IRF1 and IRF2. Interestingly, VOL. 17, 1997 REGULATION OF Qp ACTIVITY BY IRF1 AND IRF2 883 both of these promoters drive transcription of genes which are intimately involved in DNA replication (production of the histone H4 gene FO108 product is cell cycle regulated and coupled to DNA replication; the EBNA1 protein is required for latent replication of the EBV genome), perhaps suggesting that IRF1 and IRF2 play a generalized role in the regulation of eukaryotic DNA replication. EMSA results presented in Fig. 12A provide evidence that HMG-I(Y) is a constituent of the other major complex which binds in the positive regulatory domain of Qp. Qp is thus similar to the IFN-␤ and VCAM-1 promoters, which have binding sites for HMG-I(Y) and IRF1-IRF2 (53, 82, 84) . As shown in Fig. 10 , all three of these promoters have an ICS which is not IFN responsive and has a G at position 14, rather than the C which is found in IFN-inducible ICS elements. It thus seems that the IRF1 and IRF2 complexes which bind to the ICS(G-14) often cooperate with HMG-I(Y) to positively regulate transcription.
We speculate that, as illustrated in Fig. 13 , (Fig. 13) . A number of proteins have been shown to associate with HMG-I(Y), including NF-B p50 (82, 84, 93) , Oct-6 (36), Oct-2A (1), Elf-1 (23), and ATF-2 (9, 93) . Current investigations are directed towards determining whether these and/or other proteins are associated with HMG-I(Y) in these Qp EMSA complexes.
The mechanism by which EBNA1 downregulates transcription from Qp has not been elucidated. Evidence indicates that each EBNA1 site contributes equally to repression, that the summed effects of the two sites are additive (not synergistic), and that the mechanism does not involve a simple blockade of polymerase progression by EBNA1 (73) . One possibility, illustrated in Fig. 13 , is that the binding of EBNA1 to Qp physically displaces the HMG-I(Y)-containing complex, thereby preventing transcription initiation or greatly diminishing its efficiency. However, since the complex containing HMG-I(Y) appears to have DNA contacts in the region of the upstream Qp EBNA1 binding site, but not the downstream EBNA1 binding site, a more elaborate mechanism may be required to explain the observation that each EBNA1 site mediates repression of Qp with equivalent efficiency.
It has recently been shown that HMG-I(Y) is a DNA bending protein (11, 61) and that positive regulation of transcription by HMG-I(Y) is dependent upon this bending property (11) . Investigation of the mechanism by which the binding of EBNA1 to the EBV latency origin of replication (oriP) makes possible the replication of the EBV episome has revealed that EBNA1 is also a DNA bending protein. Two EBNA1 dimers bound to properly spaced adjacent sites interact to effect a major bend in the DNA helix and by a distinct mechanism, a single EBNA1 dimer bound to DNA induces a less substantial bend (reviewed in reference 7). Given that the spacing of the Qp EBNA1 sites is such that the two dimers would be on opposite sides of the DNA helix (3, 24) , only the second mechanism is likely to be operative. Repression may thus be a result of the EBNA1-induced DNA bending distorting the bend induced by HMG-I(Y) in such a way that transcription is no longer facilitated by HMG-I(Y). Perhaps it is more likely, since HMG-I(Y) has been shown to bind to the minor grove of DNA with little sequence specificity but high specificity for specific conformations of DNA (61) , that repression by EBNA1-induced bending lowers the affinity of HMG-I(Y) for the Qp regulatory region, thereby facilitating the "competition" illustrated in the model shown in Fig. 13 via local distortion of the DNA helix.
